Enanta Pharmaceuticals, Inc. Aktie News

WATERTOWN, Mass.—(BUSINESS WIRE)—Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich der Entwicklung von kleinmolekularen Arzneimitteln für Virusinfektionen und immunologische Erkrankungen widmet, gibt heute bekannt, dass Jay R. Luly, Ph.D., 70 Jahre, bis zum 1. Februar 2027 als President und Chief Executive Officer in den Ruhestand tr...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), ein im klinischen Stadium befindliches Biotechnologieunternehmen, das sich der Entwicklung von Small‑Molecule‑Medikamenten für virale Infektionen und immunologische Erkrankungen widmet, gab heute bekannt, dass der erste Patient in RESOLVE dosiert wurde, seiner globalen Phase‑2b/3‑Studie zu zelicapavir bei Erwachsenen...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), ein im klinischen Stadium befindliches Biotechnologieunternehmen, das sich der Entwicklung kleiner Molekülwirkstoffe für Virusinfektionen und immunologische Erkrankungen widmet, berichtete heute über die Finanzergebnisse für sein am 30. Juni 2026 endendes drittes Fiskalquartal. „Im Quartal haben wir weiterhin Momentu...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV i...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jeffe...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026. “Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked dilige...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the A...